H.u.group Holdings, Inc. · TSE:4544
H.u.group — Q3 FY2024 Earnings Presentation
21 slides from H.u.group's earnings presentation, Feb 7, 2025
Slide 1: Financial Results for the Third Quarter of FY2024
Financial Results for The Third Quarter of FY2024 (Ended December 31, 2024) Feb. 7, 2025 (TSE: 4544)
Slide 2: Notes & references
Notes & references: * The financial information in this document follows Japanese GAAP, with the exception for EBITDA (Operating Profit + Depreciation + Goodwill Impairment), which is a non-GAAP measure. * In some cases, “Net profit/loss attributable to shareholders of the parent company” may be abb
Slide 3: Executive Summary
Executive Summary • Sales increased by 4.5 billion yen YoY, with EBITDA and operating profit The each growing by 3.8 billion yen Group • The full-year forecast was revised downward due to shortfalls in LTS cost reductions and other factors 1 • Base business recovery drove a 7% YoY sales increase • P
Slide 4: Financial Results for the Third Quarter of FY2024
Financial Results for The Third Quarter of FY2024 3
Slide 5: Consolidated Results for 9 Months FY2024
Consolidated Results for 9 Months FY2024 (\ billion) 9 Months FY2023 9 Months FY2024 Profit Profit Change Results Results ratio ratio Net sales 177.51 182.05 +4.54 +2.6% LTS 109.96 115.06 +5.10 +4.6% IVD 46.43 45.07 -1.36 -2.9% HS 21.13 21.92 +0.79 +3.7% Operating profit/loss 1 -1.15 -0.6% 2.66 1.5%
Slide 6: Consolidated Net Sales Changes
Consolidated Net Sales Changes (\ billion) 190 +5.10 -1.36 +0.79 182.05 1 180 177.51 5.47 1 Decrease in COVID-19 tests: -46.0% 10.11 170 167.40 Growth in base business: +5.5% 176.58 0 160 9 months LTS IVD HS 9 months FY23 FY24 1. Net sales related to COVID-19 testing 5
Slide 7: Consolidated Operating Profit Changes
Consolidated Operating Profit Changes (\ billion) 4 +4.97 -1.72 3 +0.35 +0.21 2.66 2 (-) COVID-19-related profit decreased in line with sales 1 -1.15 0 -1 (+) Positive Impact from profit improvement measures (+) Profit increase driven by sales growth (+) Reduced costs related to AkirunoCube -2 9 mon
Slide 8: Quarterly Performance Trend
Quarterly Performance Trend Net sales EBITDA, OP (\ billion) Net sales related to (\ billion) Net sales EBITDA Operating Profit 90 COVID-19 testing 45 75.1 70.2 68.8 65.3 66.9 63.5 64.1 62.1 23.2 59.9 59.9 61.0 59.4 59.5 60.5 60 18.7 12.3 15.0 11.4 56.6 3.2 2.1 1.9 30 12.9 11.8 4.0 2.5 1.5 6.4 2.9 6
Slide 9: Consolidated Ordinary Profit/Loss & Net Profit/Loss
Consolidated Ordinary Profit/Loss & Net Profit/Loss Ordinary Profit/Loss Net Profit/Loss (\ billion) (\ billion) 6 6 4.29 4 4 2.79 2 2 -2.86 -3.35 0 0 -2 -2 -4 -4 9 Months 9 Months 9 Months 9 Months FY23 FY24 FY23 FY24 Major non-operating factors Major factors affected to net profit ・Gain on investm
Slide 10: LTS
LTS Quarterly Results YoY Comparison Net sales EBITDA, OP (\ billion) (\ billion) (\ billion) 50 20 9 Months 9 Months Change FY23 FY24 37.7 37.7 38.8 38.5 Net sales 109.96 115.06 +5.10 +4.6% 36.8 Off-site 88.46 93.57 +5.12 +5.8% 0.7 1.1 1.0 1.3 1.8 6.1 6.3 6.3 FMS/Branch 18.43 18.65 +0.22 +1.2% 6.1
Slide 11: LTS: Trend in the Testing Volume (since April 2020)
LTS: Trend in the Testing Volume (since April 2020) • Testing volume is increasing with COVID-19 changed to a Category 5 Infectious Disease and the end of dedicated hospital bed allocations • Baseline growth continues in the post-COVID-19 era The trend assumes the tests-per-day at SRL in FY2019 to b
Slide 12: IVD
IVD Quarterly Results YoY Comparison Net sales (\ billion) EBITDA, OP (\ billion) (\ billion) 24 16 9 Months 9 Months Change FY23 FY24 Net sales 46.43 45.07 -1.36 -2.9% Lumipulse 19.64 19.56 -0.08 -0.4% Japan 17.11 15.19 -1.91 -11.2% 16.2 16.1 Overseas 2.54 4.37 +1.83 +72.1% 15.5 14.4 14.6 CDMO etc.
Slide 13: HS Quarterly Results YoY Comparison
HS Quarterly Results YoY Comparison Net sales EBITDA, OP (\ billion) (\ billion) (\ billion) 10 2 9 Months 9 Months Change FY23 FY24 Net sales 21.13 21.92 +0.79 +3.7% 7.3 7.5 Sterilization 16.44 17.20 +0.76 +4.6% 7.1 7.2 7.1 Home-visiting, 4.69 4.72 +0.03 +0.7% 1.6 1.6 welfare 1.6 1.6 1.5 EBITDA Rat
Slide 14: Consolidated Cash Flows (YoY)
Consolidated Cash Flows (YoY) Operating Cash Flows Free Cash Flows (\ billion) (\ billion) 13.1 9.4 13.1 +1.3 +0.2 9.4 -9.2 -11.8 1 9 Months 9 Months FY23 FY24 Operating CF Investment CF FCF 1. NWC：Net Working Capital （Including changes in 'other current liabilities' and 'other non-current liabiliti
Slide 15: Cash and Deposits / Interest-bearing Debts
Cash and Deposits / Interest-bearing Debts (\ billion) FY2023 FY2024 Cash and deposits Short-term debts 40.4 47.0 39.9 37.3 Bonds due within Cash and 30.9 Interest- one year deposits bearing Long-term debts debts Interest-bearing 10.0 10.0 10.1 debts 29.0 Lease debts 10.0 29.0 29.0 29.2 Bonds payabl
Slide 16: FY2024 Full-Year Forecast
FY2024 Full-Year Forecast 15
Slide 17: Revision of FY2024 Full-year Forecast
Revision of FY2024 Full-year Forecast FY2024 (\ billion) FY2023 Previous Current vs vs 1 results forecast forecast FY2023 previous forecast Net sales 237.0 241.0 241.0 +4.0 +1.7% ー ー EBITDA 16.8 31.0 25.5 +8.7 +51.5% -5.5 -17.7% OP -4.0 10.0 4.5 +8.5 ー -5.5 -55.0% Ord. profit -7.2 8.5 6.0 +13.2 ー -2
Slide 18: Timeline for Completing the Transfer to AkirunoCube
Timeline for Completing the Transfer to AkirunoCube • Reporting system transfer completed • All system transfer will be completed by the end of March (forecast is unchanged) CY2024 CY2025 Apr.-Jun. Jul.-Sep. Oct.-Dec. Jan.-Mar. Apr.-Jun. Jul.-Sep. Duration of one-time costs Old system shutdown Esote
Slide 19: Appendix
Appendix 18
Slide 20: AkirunoCube Costs and Effects
AkirunoCube Costs and Effects • Starting from Q1 of FY2024, the AkirunoCube-related figures will include system-related costs and other impacts associated with AkirunoCube • The full-year forecast was partially revised FY2023 FY2024 (\ billion ) Previous Current Full-year Q1 Q2 Q3 full-year full-yea
Slide 21: Contact information
【Contact information】 IR/SR Department Email : ir@hugp.com Disclaimer regarding forward-looking statement: The performance forecast provided in this document is prepared by the management based on currently available information and various hypotheses and ideas including significant risks or uncerta
H.U. Group Holdings — Q3 FY2024 Earnings Presentation on 6ix